SBA & Funding Data for This Sector

Infusion pump accessories distribution sits inside NAICS code 423450 — Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers. The SBA's small-business size standard for this code is 200 employees or $15 million in average annual receipts, which puts almost every independent accessories distributor comfortably inside SBA-eligible territory for 7(a) lending and government set-aside contracting.

That matters because this is an inventory-heavy business: unlike a services company that can bootstrap on sweat equity, a distributor needs cash sitting on shelves before the first invoice goes out. SBA 7(a) loans (up to $5 million, terms up to 25 years for real-estate-backed facilities, 10 years for inventory and working capital) are the most common route we see clients use to bridge that gap, precisely because conventional bank underwriting is cautious about lending against medical disposables inventory without a lender-ready forecast attached. The SBA guarantees a portion of the loan (typically up to 85% on smaller facilities), which is what makes conventional lenders willing to underwrite inventory-heavy medical distribution in the first place — but that guarantee doesn't remove the lender's own diligence on your regulatory readiness, which is exactly where under-prepared plans stall.

Where the named vendors already in this market fit in: national players like Medline and specialty biomedical parts marketplaces like PartsSource compete on breadth and logistics scale, while smaller specialist suppliers such as Chemyx (syringe and infusion pump accessories) and United Infusion (patient-facing home infusion retail) compete on category depth and service. None of them dominate every account — hospital biomedical departments routinely single-source specific SKUs from two or three vendors simultaneously to avoid supply concentration risk, which is precisely the opening a new, well-documented regional distributor can compete for.

In our experience, the single biggest thing that separates a funded application from a declined one in this category isn't the size of the ask — it's whether the plan shows a documented path to a quality management system and a realistic account-acquisition sequence, rather than assuming hospital volume shows up on day one. Lenders who see medical-device paper have learned to distrust plans that skip straight to "we sell to hospitals" without addressing procurement gatekeepers.

Funding Routes Outside the US

In the UK, the Start Up Loans scheme now offers up to £25,000 per founder (up to £100,000 across a four-founder team) at a fixed 7.5% interest rate as of April 2026, repayable over 1-5 years with no arrangement or early-repayment fees. From April 2026 the scheme also extended eligibility to businesses that have been trading for up to 60 months, which helps founders who've already been running a smaller-scale supply operation and now want to formalise and scale it. For a lean, home-infusion-focused launch this can realistically cover opening inventory and the first round of MHRA/UKCA registration costs without needing a larger commercial facility.

Founders looking at Canada should note that distributors of Class II-IV medical devices there need a Medical Device Establishment License (MDEL) from Health Canada, required for importers and distributors regardless of the device class being handled, alongside the manufacturer's own Medical Device License (MDL) for the products themselves (Health Canada's Medical Devices Active Licence Listing). BDC (Business Development Bank of Canada) financing and provincial small-business loan guarantees are the typical funding routes once that licensing is in place.

Market Size, Demand & Growth

The global infusion pump market is valued at $19.9 billion in 2025 and is projected to reach $28.3 billion by 2030, a 7.4% compound annual growth rate, according to MarketsandMarkets. A separate analysis from Allied Market Research pegs the combined pumps-and-accessories market at $13.2 billion by 2030, growing 5.0% annually — the spread between estimates reflects different scoping of what counts as an "accessory" versus a standalone durable good.

What matters more to a new business than the headline figure is the segment mix. According to Business Research Insights, the accessories and disposables category — infusion sets, catheters, tubing, and connectors — held approximately 53% of the combined market in 2024. That's the whole thesis for this business: pumps get purchased once every 5–8 years on a capital budget, but the disposables around them get bought every week on an operating budget, which is a structurally different (and stickier) sales motion.

Who actually signs the purchase order matters as much as the market size figure. In hospitals, that's typically a materials management or supply chain director working from a GPO contract catalogue, with a biomedical engineering or clinical engineering lead signing off on pump compatibility. In home infusion, it's usually the specialty pharmacy owner or a home infusion nurse manager making the call directly, with far less procurement bureaucracy in between. Your plan's marketing and sales section should name which of these buyers you're building a relationship with first, because the sales motion for each is different: hospital supply chain wants contract pricing and fill-rate guarantees in writing, while home infusion buyers respond more to direct relationship and responsiveness.

Demand drivers are unglamorous but durable: rising chronic disease prevalence (diabetes, cancer, cardiovascular disease), an ageing population that needs more home-based infusion therapy, and hospitals steadily shifting infusion volume out of acute wards and into ambulatory and home settings where accessories reorder cadence is different but no less frequent. In the UK, the same demand pattern plays out against an NHS backdrop that increasingly favours community and home infusion pathways to free up inpatient capacity — a trend that favours suppliers who can serve home infusion providers, not just hospital pharmacy.

The home infusion channel specifically is worth planning around on its own terms rather than as an afterthought to hospital sales. The US home infusion therapy market was estimated at $21.95 billion in 2025 and is projected to reach $39.96 billion by 2033, a 7.78% CAGR, according to a Grand View Research market report — growing faster than the acute-care pump market it sits alongside. The demographic tailwind behind that number is stark: the US population aged 65 and over is projected to roughly double from 52 million in 2018 to 95 million by 2060, and CDC data published in 2025 found that 76.4% of US adults (more than 194 million people) had at least one of twelve tracked chronic conditions in 2023, with 51.4% carrying multiple chronic conditions simultaneously. Every one of those patients who moves from an inpatient infusion chair to a home infusion pump is a new, recurring accessories account that never shows up in a hospital-only sales plan.

The competitive reality worth understanding before you write a word of your plan: five manufacturers — B. Braun, Baxter, ICU Medical, BD (through its Alaris pump line), and Fresenius Kabi — dominate pump placement, and each locks hospitals into proprietary, pump-specific administration sets. That's both the barrier and the opportunity. It's a barrier because you can't simply source generic tubing for a hospital that's standardised on Alaris pumps — you need OEM-compatible or OEM-authorized stock. It's an opportunity because OEM quality events create real openings: Fresenius Kabi issued a Class I recall in 2025 for Ivenix large-volume pump administration sets after some units shipped with the drip chamber and Luer Lock assembled in reversed positions, and separately recalled software (v5.10.2) after a false battery-depletion alarm risked unplanned pump shutdowns, with a fix not expected until July 2026 (FDA recall notice). BD's infusion pump unit, meanwhile, has operated under an amended FDA consent decree since 2009 (inherited from CareFusion/Cardinal Health) and received an additional Form 483 inspection observation in May 2024. Hospitals watching their primary OEM stumble on quality are a receptive audience for a distributor who can prove traceability discipline.

What It Costs to Launch an Infusion Pump Accessories Business

Launching an infusion pump accessories distribution business typically requires $65,000 to $310,000 (£52,000 to £245,000) in the US and UK respectively, depending on how many OEM product lines you carry, whether you hold your own regulatory registrations or operate under a partner's, and how much working capital you need before receivables catch up with inventory spend.

For context on cost structure across the wider medical supply category: general durable medical equipment resellers can launch on $15,000-$75,000, while pharmaceutical-adjacent distributors run $250,000-$500,000, according to Growthink and BizFundingResource. Infusion pump accessories sit in between: not pharmaceutical, but genuinely patient-contact devices that carry FDA establishment registration costs (roughly $11,423/year where registration is required) that a generic bandages-and-braces distributor never has to budget for.

The mistake we see most often at this stage is under-costing the regulatory line item because a founder assumes "we're just reselling parts someone else already got cleared." Accessories inherit scrutiny from the parent device classification — skipping ISO 13485-aligned documentation now is the single most common reason plans stall when a lender or an OEM partner asks for it later.

Bridging the Cash Flow Gap

The financing timeline that trips up first-time founders isn't the loan approval itself — it's the gap between when inventory has to be paid for and when hospital or home infusion accounts actually pay their invoices. Most healthcare-sector purchasers run 30-60 day payment terms, which means a distributor carrying $80,000 in active inventory against $50,000 in monthly sales needs working capital to cover roughly two full sales cycles before cash starts recycling on its own. Your financial model should show this gap explicitly rather than assuming revenue converts to cash the moment a set ships — it's one of the fastest ways to demonstrate to a lender that you understand distribution economics rather than just the market opportunity.

Revenue Model & Unit Economics

Administration sets and tubing typically wholesale between $3 and $14 per single-use unit depending on pump compatibility, with proprietary OEM-specific cassette sets commanding the top of that range. Filters and clamp assemblies run $2 to $9 per unit. Gross margins on disposables distribution generally sit at 22-38%, compressing to an 8-16% net margin once warehousing, compliance overhead, and field sales cost are layered in.

Here's a worked example we build into client plans: a distributor supplying administration sets and tubing to a 220-bed regional hospital network at an average $6.40 per set, with that network running roughly 340 sets per day across its infusion population, generates approximately $2,175 in daily set revenue — about $793,000 annually from that single hospital account, before filters, clamps, and a separate home-infusion channel are added on top.

What makes this category different from most business-plan-template niches is that the reorder cycle is clinically dictated, not discretionary. Standard practice is to change primary administration sets every 24-96 hours depending on the infusate — lipid and blood-product lines change more frequently than plain crystalloid lines — which means volume tracks patient census almost mechanically once you have an account, rather than depending on repeat marketing. Home infusion patients reorder on a slower weekly-to-monthly cycle but at retail-adjacent pricing that partly offsets the lower unit velocity.

Additional revenue layers worth planning for: consignment stock arrangements with smaller hospitals (you hold inventory on their shelves and bill on usage, which improves your account stickiness at the cost of tying up more of your own capital), value-added services like automated par-level replenishment software integration, and biomedical repair-parts sales alongside consumables for hospitals maintaining older pump fleets.

Additional Revenue Streams to Model

• Consignment inventory billing: stock held on a customer's site and invoiced monthly on actual usage, common with mid-size hospitals that don't want to carry the inventory risk themselves
• Par-level replenishment contracts: automated reordering tied to a scanning or RFID system, typically commands a service fee on top of unit pricing
• Biomedical repair parts: clamp assemblies, interface cables, and battery packs for hospitals maintaining older pump fleets rather than replacing them outright
• Home infusion starter kits: bundled tubing, filters, and dressing supplies sold directly to home infusion pharmacies at a bundled margin above individual-unit pricing
• Emergency/back-order fulfilment: premium pricing for rapid-turnaround orders when a hospital's primary OEM supply is disrupted, which is exactly the scenario a recall like the 2025 Ivenix administration-set issue creates

Pricing conversations with hospital accounts almost always run through GPO contract tiers, so your financial model should build in a realistic contracted-price assumption rather than list price — the gap between the two is frequently 15-25%, and a plan that models list price throughout will overstate margin to a reader who knows the category.

Three Ways to Structure This Business

"Infusion pump accessories business" isn't one business model — it's at least three distinct ones with different capital needs, different sales cycles, and different funding stories. Your plan should pick one and defend it, not hedge across all three.

Most first-time founders default to the independent multi-brand model because it sounds like the biggest addressable market, but it's also the one most exposed to price competition from the OEMs' own direct-supply teams. The home infusion specialty path is under-served precisely because it looks smaller on paper — which is exactly why it's often the more fundable story for a first plan: smaller capital ask, faster sales cycle, and a growth market (home-based care) that hospital-focused competitors are structurally slow to chase.

In funding terms, the three models map roughly onto our startup-cost figures above: an OEM-authorized reseller launch tends to land at the top of the $65,000-$310,000 range because minimum stocking commitments are set by the OEM, not by you; an independent multi-brand distributor sits in the middle, scaled to however many product lines you commit to on day one; and a home infusion specialty supplier is realistically achievable at the lower end, which is one reason we recommend it as a first plan for founders without an existing hospital relationship to lean on. Whichever model you choose, name it explicitly in your executive summary — a plan that reads as "we'll do a bit of all three" is the fastest way to lose a lender's confidence that you understand your own go-to-market.

Licensing: US, UK, EU & Canada

Before the country-by-country detail, one obligation runs across all four jurisdictions and belongs in every plan's operations section: post-market surveillance and adverse-event reporting. If an accessory you distribute is implicated in a patient-safety incident, you have a reporting obligation to the relevant regulator — the FDA's Medical Device Reporting (MDR) programme in the US, MHRA's device-specific vigilance reporting in the UK, and the equivalent incident-reporting duty for economic operators under EU MDR 2017/745. This is precisely the discipline the 2025 Fresenius Kabi Ivenix recalls tested at scale, and it's why lenders and OEM partners alike treat a documented vigilance procedure as a baseline requirement, not a nice-to-have.

United States

• FDA Class II clearance: infusion pumps clear via 510(k) under 21 CFR 880.5725; compatible accessories generally inherit this classification rather than needing a fully separate submission
• FDA establishment registration & device listing: annual fee, currently around $11,423/year for facilities that handle regulated devices
• State medical device / wholesale drug distributor licensing: requirements vary by state, typically $500-$5,000 and 4-12 weeks to process
• UDI (Unique Device Identifier) compliance: required labelling and database submission under 21 CFR 801.20
• Average 510(k) review timeline: 3-6 months per RegDesk's FDA infusion pump guidance overview

United Kingdom

• MHRA device registration: as of April 2026 there is no upfront registration fee; instead an annual fee of £300 applies per GMDN Level 2 category, per Casus Consulting's MHRA registration guide
• UKCA or CE marking: infusion pumps and compatible accessories fall under Class IIb, requiring Notified Body conformity assessment
• Registration turnaround: official target of 5 business days; most straightforward applications clear in 1-2 business days
• UK Responsible Person: mandatory if the manufacturer/distributor is based outside the UK

European Union

Under EU MDR 2017/745, infusion pumps and their compatible accessories are classified Class IIb — the "medium-to-high risk, long-term or critical-function device" tier alongside ventilators, per Registrar Corp's Class IIb overview. Notified Body involvement is mandatory for conformity assessment, and first-time certification typically runs 6-12 months given the volume of clinical and technical documentation required.

Canada

Distributors and importers of Class II-IV medical devices in Canada — which covers most infusion pumps and their compatible accessories — must hold an active Medical Device Establishment License (MDEL) from Health Canada, a requirement that applies regardless of device class, per Health Canada's Medical Devices Active Licence Listing. The manufacturer separately holds a Medical Device License (MDL) for the product itself; a distributor's job is to keep its own MDEL current and confirm every product it carries maps to an active MDL before it goes on the shelf.

Our Research + Content package includes jurisdiction-specific regulatory citations built into your plan's licensing section, so lenders and OEM partners see you've actually mapped the pathway rather than gesturing at "we'll get the necessary approvals."

Five Mistakes That Sink New Entrants

1. Competing purely on unit price against OEM direct-supply contracts. Hospitals that already have a direct relationship with B. Braun, Baxter, or ICU Medical will rarely switch for a few cents off a tubing set — they switch for fill-rate reliability, faster back-order resolution, and account service the OEM's own logistics team can't match at scale.
2. Launching hospital-facing sales without a GPO contract strategy. Most US hospital systems route the bulk of disposables spend through Vizient, Premier, or HealthTrust, and procurement teams are often contractually restricted from buying outside those agreements. Plans that assume direct hospital sales from day one routinely stall for months once this becomes clear.
3. Delaying UDI-compliant serialized traceability until after a scare. The 2025 Fresenius Kabi Ivenix recall is a live example of why: when a defect surfaces, the suppliers who can trace every lot to every account in hours look credible, and the ones who can't look like a liability a hospital can't afford to keep working with.
4. Underinvesting in an ISO 13485-aligned quality system. This single document set is usually the gatekeeper for authorized-reseller agreements with the major OEMs — without it, you're locked out of the exact partnerships that make a multi-brand catalogue possible.
5. Chasing acute-care hospital volume exclusively while ignoring home infusion. Home infusion has a materially different (and currently faster-growing) demand curve — $21.95 billion in 2025 growing at 7.78% annually — a lower barrier to first account, and less GPO friction. It's frequently the better first market even though it looks smaller on a market-size slide.
6. Modelling revenue at list price instead of realistic contracted pricing. The gap between list price and the GPO-contracted price a hospital actually pays is commonly 15-25%. Plans that don't account for this gap look impressive on paper and then miss their own Year 1 forecast by a wide margin, which damages credibility with the same lender for a future funding round.

Every one of these mistakes shows up in the same place: the gap between how the founder understands the business (correctly, usually — most people entering this category have real clinical or biomedical background) and how that understanding gets written down for a lender or an OEM partner who's never met them. A plan's job is to close that gap in writing, not to assume domain credibility will speak for itself.

Sample Plan Extract

Here's an extract from a business plan written by our team for this category — so you can see the level of detail we build in:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary — Your business at a glance, written to hook a lender or investor in 60 seconds
• Company Overview — Legal structure, ownership, distribution territory, and founding story
• Industry Analysis — Market size, growth trends, and the regulatory landscape specific to medical device accessories
• Customer Analysis — Hospital procurement, home infusion providers, and GPO dynamics
• Competitor Analysis — OEM direct-supply competition and independent distributor mapping
• Marketing Plan — Account acquisition sequencing, from independent accounts through to GPO contract pursuit
• Operations Plan — Inventory management, UDI traceability, and quality system documentation
• Management Team — Founder bios, regulatory affairs support, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements — formatted for SBA 7(a) underwriting review.

See also our marketing plan guide for infusion pumps accessories businesses if you're past the funding stage and building out your go-to-market sequence, or our medical supply business plan template and durable medical equipment business plan template if your catalogue extends beyond infusion-specific accessories.

The free template gives you the section structure and prompts; it won't write the regulatory citations, the GPO-contract strategy, or the unit economics for you. That's the gap our $300/£250 Research + Content package closes — our team researches your specific product lines, jurisdictions, and target accounts and writes the narrative around them, so what you submit to a lender reads like it was written by someone who has actually sold into this category, not assembled from a generic template.

Frequently Asked Questions